Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Korro Bio (KRRO), Oruka Therapeutics (ORKA) and Gilead Sciences (GILD)

Tipranks - Tipranks - Sat Mar 14, 4:19AM CDT

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Korro Bio (KRRO – Research Report), Oruka Therapeutics (ORKA – Research Report) and Gilead Sciences (GILD – Research Report).

Claim 70% Off TipRanks Premium

Korro Bio (KRRO)

William Blair analyst Myles Minter reiterated a Buy rating on Korro Bio today and set a price target of $11.50. The company’s shares closed last Thursday at $11.50.

According to TipRanks.com, Minter is a top 100 analyst with an average return of 39.4% and a 63.0% success rate. Minter covers the Healthcare sector, focusing on stocks such as Contineum Therapeutics, Inc. Class A, CAMP4 Therapeutics Corporation, and Neumora Therapeutics, Inc. ;'>

Korro Bio has an analyst consensus of Strong Buy, with a price target consensus of $21.00, implying an 83.2% upside from current levels. In a report released today, Chardan Capital also maintained a Buy rating on the stock with a $15.00 price target.

See today’s best-performing stocks on TipRanks >>

Oruka Therapeutics (ORKA)

Barclays analyst Etzer Darout maintained a Buy rating on Oruka Therapeutics today and set a price target of $50.00. The company’s shares closed last Thursday at $31.99.

According to TipRanks.com, Darout is a 5-star analyst with an average return of 27.4% and a 55.0% success rate. Darout covers the Healthcare sector, focusing on stocks such as Protagonist Therapeutics, Monopar Therapeutics Inc, and Arvinas Holding Company. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Oruka Therapeutics with a $57.78 average price target, representing a 69.9% upside. In a report issued on March 11, Jefferies also maintained a Buy rating on the stock with a $45.00 price target.

Gilead Sciences (GILD)

Barclays analyst Emily Field maintained a Hold rating on Gilead Sciences today and set a price target of $155.00. The company’s shares closed last Thursday at $145.21.

According to TipRanks.com, Field is a 3-star analyst with an average return of 0.9% and a 42.3% success rate. Field covers the Healthcare sector, focusing on stocks such as Bristol-Myers Squibb, GlaxoSmithKline, and Merck & Company. ;'>

Currently, the analyst consensus on Gilead Sciences is a Strong Buy with an average price target of $158.00.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).